ORG Wealth Partners LLC Buys 2,708 Shares of AbbVie Inc. $ABBV

ORG Wealth Partners LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 14.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,082 shares of the company’s stock after purchasing an additional 2,708 shares during the quarter. AbbVie makes up approximately 1.2% of ORG Wealth Partners LLC’s portfolio, making the stock its 11th biggest position. ORG Wealth Partners LLC’s holdings in AbbVie were worth $5,119,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ABBV. Stonehearth Capital Management LLC bought a new stake in AbbVie during the 3rd quarter valued at $213,000. Steele Capital Management Inc. grew its holdings in AbbVie by 2.3% in the 3rd quarter. Steele Capital Management Inc. now owns 13,180 shares of the company’s stock worth $3,052,000 after acquiring an additional 300 shares during the last quarter. Hidden Cove Wealth Management LLC increased its position in shares of AbbVie by 38.3% in the third quarter. Hidden Cove Wealth Management LLC now owns 1,906 shares of the company’s stock valued at $441,000 after acquiring an additional 528 shares during the period. SilverOak Wealth Management LLC raised its stake in shares of AbbVie by 10.0% during the third quarter. SilverOak Wealth Management LLC now owns 1,277 shares of the company’s stock valued at $296,000 after acquiring an additional 116 shares during the last quarter. Finally, Sonoma Allocations LLC bought a new position in shares of AbbVie during the third quarter valued at about $424,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Down 1.8%

Shares of ABBV stock opened at $220.06 on Friday. The company’s fifty day moving average price is $226.59 and its 200-day moving average price is $215.12. The stock has a market cap of $388.93 billion, a PE ratio of 166.71, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the company posted $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 496.97%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

Analysts Set New Price Targets

ABBV has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Guggenheim increased their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Morgan Stanley boosted their target price on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Evercore ISI raised their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.